Liver　cancer,　which　is　well-known　to　us　as　one　of　human　most　prevalent　malignancies　across　the　globe,　poses　a　significant　risk　to　live　condition　and　life　safety　of　individuals　in　every　region　of　the　planet.　It　has　been　shown　that　immune　checkpoint　treatment　may　enhance　survival　benefits　and　make　a　significant　contribution　to　patient　prognosis,　which　makes　it　a　promising　and　popular　therapeutic　option　for　treating　liver　cancer　at　the　current　time.　However,　there　are　only　a　very　few　numbers　of　patients　who　can　benefit　from　the　treatment　and　there　also　exist　adverse　events　such　as　toxic　effects　and　so　on,　which　is　still　required　further　research　and　discussion.　Fortunately,　the　clustered　regularly　interspaced　short　palindromic　repeat/CRISPR-associated　nuclease　9　(CRISPR/Cas9)　provides　a　potential　strategy　for　immunotherapy　and　immune　checkpoint　therapy　of　liver　cancer.　In　this　review,　we　focus　on　elucidating　the　fundamentals　of　the　recently　developed　CRISPR/Cas9　technology　as　well　as　the　present-day　landscape　of　immune　checkpoint　treatment　which　pertains　to　liver　cancer.　What’s　more,　we　aim　to　explore　the　molecular　mechanism　of　immune　checkpoint　treatment　in　liver　cancer　based　on　CRISPR/Cas9　technology.　At　last,　its　encouraging　and　powerful　potential　in　the　future　application　of　the　clinic　is　discussed,　along　with　the　issues　that　already　exist　and　the　difficulties　that　must　be　overcome.　To　sum　up,　our　ultimate　goal　is　to　create　a　fresh　knowledge　that　we　can　utilize　this　new　CRISPR/Cas9　technology　for　the　current　popular　immune　checkpoint　therapy　to　overcome　the　treatment　issues　of　liver　cancer.　©　2024　IOP　Publishing　Ltd.